Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eli Lilly Japan Files NDA for AD/HD Drug Atomoxetine
July 9, 2007
- SURVEY／3 out of 4 Women Experience Hemorrhoids
July 9, 2007
- REGULATORY NEWS IN BRIEF
July 9, 2007
- seminar／Use of New Anticancer Agents Should Be Restricted to Specialists for Fixed Period
July 9, 2007
- JGPMA to Discuss Full Membership Affiliation with the IGPA
July 9, 2007
- Differences in Opinion over Generics Sharpen between JMA and Bill Payers
July 9, 2007
- 27% Sales Growth for Philips Medical Systems in Japan in 2006: Dr Smit
July 9, 2007
- seminar／Generic Substitution Essential to Further Promote Use of Generics: Dr Masuhara
July 9, 2007
- Eisai Aims at 20% Increase in Sales of Actonel with Once-Weekly Formulation
July 9, 2007
- GENERICS NEWS IN BRIEF
July 9, 2007
- Yakult Licenses Anticancer Agent Satraplatin from GPC Biotech
July 9, 2007
- Cephalon to File NDA for Bendamustine in US: SymBio
July 9, 2007
- GSK Deploys 630 Specialist MRs to Promote Adoair
July 9, 2007
- Nat'l Centers Should Form Healthcare Clusters to Promote Clinical Research
July 9, 2007
- GSK to Launch 5 New Drugs for Cancer in Next 3 Years
July 9, 2007
- R&D NEWS IN BRIEF
July 9, 2007
- MediBIC Group Announces Restructuring Plan to Focus on PGx
July 9, 2007
- NAG Increases Water Content in the Skin: Dr Tsubouchi
July 9, 2007
- Merger with MPC Approved by Tanabe's Shareholders
July 9, 2007
- SELF-MEDICATION NEWS IN BRIEF
July 9, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…